A Study to Evaluate the Safety, Tolerability, MTD, PK, and Activity of Oraxol in Subjects w Adv. Malignancies
This is a multicenter, open-label, safety study. Eligible subjects will be adults with advanced malignancies. The study includes a pretreatment and treatment phase. The pretreatment phase consists of screening and baseline periods. The treatment phase consists of 4-week treatment periods and a follow-up period.
Solid Tumor
DRUG: Oraxol
Maximum tolerated dose (MTD) of Oraxol, The highest dose at which no more than 1 of 6 subjects experience a dose-limiting toxicity (DLT) during treatment, 20 weeks
Evaluate tumor response, RECIST v1.1 criteria defined as complete response, partial response, stable disease or progressive disease, At baseline and every 8 weeks through study completion, approximately 24 months|Number of Participants with abnormal laboratory values and/or adverse events that are related to treatment, Number of Participants with abnormal laboratory values and/or adverse events that are related to treatment, 4 weeks|The amount of Oraxol in the blood stream, The measurement of Oraxol levels in the blood stream over time, 3 weeks|The recommended Phase 2 dose of paclitaxel as Oraxol, The totality of information from the number of participants that reach the MTD (outcome #1), the number of participants that experience abnormal laboratory values and/or adverse events that are related to treatment (outcome #3), and the amount of Oraxol in the blood stream in participants (outcome #4), 24 months
This is a multicenter, open-label, safety study. Eligible subjects will be adults with advanced malignancies. The study includes a pretreatment and treatment phase. The pretreatment phase consists of screening and baseline periods. The treatment phase consists of 4-week treatment periods and a follow-up period.